Tetsuya Yamagata

Tetsuya Yamagata

Company: Modalis Therapeutics

Job title: Chief Scientific Officer


Dr. Yamagata serves as the Chief Scientific Officer at Modalis Therapeutics, advancing the development of a novel therapeutic platform using epigenetic editing technology since 2016. Under his leadership, Modalis’ lead program has emerged as one of the frontrunners among pipelines in burgeoning peer companies. With over 15 years of experience in biotechnology, Dr. Yamagata possesses specialized expertise in immunology, molecular biology, and genetics. His extensive medical background includes dedicated years treating cancer patients with haematological disorders. Leveraging his profound knowledge of biomedical science, Dr. Yamagata aims to address unmet medical needs through tackling the most promising indications for epigenetic medicine.

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.